Short Summary
ResMed Corp. successfully convinced the PTAB to institute IPR proceedings against Cleveland Medical Devices, Inc.'s patent (No. 11690512). The Board found that ResMed demonstrated a reasonable likelihood of prevailing on Ground 1, allowing the challenge to proceed despite neutral merits.
Detailed Summary
ResMed Corp. challenged U.S. Patent No. 11690512 owned by Cleveland Medical Devices, Inc. in an IPR proceeding based solely on obviousness (35 U.S.C. § 103). The Board analyzed the discretionary denial factors under Fintiv and determined that while the merits were neutral, Petitioner sufficiently demonstrated a reasonable likelihood of prevailing on Ground 1. Consequently, the Board granted institution, allowing ResMed to proceed with its challenge against claims 1-20 in the healthcare/sleep diagnostics technology space.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in ResMed Corp. vs Cleveland Medical Devices, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Intas Pharmaceuticals, Ltd. et al.vsAtossa Therapeutics, Inc.
Intas Pharmaceuticals and Atossa Therapeutics filed a joint request to keep their settlement agreement confidential under 35 U.S.C. §317 and to terminate the pending IPR on patent 11,261,151.
smaXtec Inc. et al.vsST Reproductive Technologies, LLC
The PTAB found several claims of the '644 patent unpatentable based on anticipation (35 U.S.C. § 102) and obviousness (35 U.S.C. § 103). The Board concluded that prior art references, specifically Harvey and Riskey, disclosed all elements of key claims related to animal monitoring bolus sensors.
RingConn, LLCvsOuraring Inc. et al.
RingConn has filed a post‑grant review petition seeking cancellation of all 18 claims of Oura’s wearable ring patent, alleging obviousness over multiple prior‑art references and §112 defects. The petition also argues the Board should not deny institution under §325(d) or §314(a).
AdvanCell Pty Ltd.vsSciencons AS et al.
AdvanCell has filed a PGR petition seeking cancellation of all 38 claims of U.S. Patent 12,249,437, arguing anticipation, obviousness, and indefiniteness based on prior art from Hassfjell‑Hoff, Norman, IAEA, and Westrøm.
Samsung Electronics Co., Ltd. et al.vsXiFi Networks R&D, Inc.
The USPTO denied XiFi Networks' request to overturn the institution of Samsung's Wi‑Fi patents, finding no good cause for a deadline extension and insufficient justification for differing claim constructions.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.